舒泰神(300204) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥123,340,760.08, representing a 6.83% increase compared to ¥115,456,600.40 in the same period last year[4] - The net profit attributable to shareholders was -¥24,409,475.07, a decrease of 22.61% from -¥19,908,114.39 year-on-year[4] - The company's basic earnings per share decreased by 25.00% to -¥0.05 from -¥0.04 in the same period last year[4] - Net loss for Q1 2022 was CNY 24,409,475.07, compared to a net loss of CNY 19,908,114.39 in Q1 2021, indicating a deterioration in financial performance[28] - The comprehensive income attributable to the parent company's owners for Q1 2022 was -73,058,069.38 CNY, compared to -45,349,095.05 CNY in the same period last year, reflecting a decline[29] Cash Flow - The net cash flow from operating activities was -¥36,899,357.21, reflecting a 21.18% decline compared to -¥30,451,157.09 in the previous year[4] - Cash inflow from operating activities totaled 169,602,753.13 CNY, up from 131,836,228.43 CNY year-over-year, indicating a growth of approximately 28.6%[31] - Cash outflow from operating activities was 206,502,110.34 CNY, compared to 162,287,385.52 CNY in the previous year, resulting in a net cash flow from operating activities of -36,899,357.21 CNY, worsening from -30,451,157.09 CNY[31] - The net increase in cash and cash equivalents for the period was 18,306,773.64 CNY, down from 35,851,527.92 CNY year-over-year[32] - The ending balance of cash and cash equivalents was 103,317,418.33 CNY, compared to 176,425,786.25 CNY at the end of the same period last year[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,737,202,545.50, down 4.91% from ¥1,826,985,153.57 at the end of the previous year[5] - Total liabilities decreased to CNY 259,521,481.24 from CNY 276,246,019.93 in the previous year[25] - The company's trading financial assets decreased to ¥301,522,904.80 from ¥381,456,190.48, reflecting a decline of about 21%[23] - The total equity attributable to shareholders decreased to CNY 1,477,681,064.26 from CNY 1,550,739,133.64 in the previous year[26] Research and Development - The company's R&D expenses increased by 35.68% to ¥1,824,098.27 due to new capitalized R&D projects[9] - Research and development expenses for Q1 2022 were CNY 58,460,631.70, slightly up from CNY 58,287,906.19 in the same period last year[26] Other Financial Metrics - The company's cash received from other operating activities increased by 454.92% to ¥8,912,476.53, primarily due to funding from a key project in Beijing[12] - The company reported a significant increase in other current assets by 1942.99%, totaling an increase of ¥15,347,225.35, attributed to fixed-income financial products purchased during the period[8] - The company's accounts receivable decreased by 33.34%, amounting to a reduction of ¥39,717,041.88, mainly due to improved sales collections[8] - The company's accounts receivable notes increased from ¥38,759,245.44 to ¥43,667,923.97, showing an increase of about 12.5%[23] - Other comprehensive loss for Q1 2022 was CNY 48,648,594.31, compared to a loss of CNY 25,440,980.66 in Q1 2021[28] Shareholder Information - The total number of restricted shares at the end of the period was 5,744,193, with 5,213,820 shares released during the period[17] - The company was unable to complete the issuance of shares to specific targets within the approval period, leading to the expiration of the registration approval[19] Clinical Trials - The company completed the first administration of the STSA-1002 injection in a Phase I clinical trial for severe COVID-19 on January 13, 2022[18] - The first administration of the BDB-001 injection for ANCA-associated vasculitis was completed on February 25, 2022[20] - The company received a drug production license change approval on March 18, 2022, allowing for an increase in production scope and address[20] Audit Status - The first quarter report was not audited[33]